Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide (LSD) administration in healthy participants

This pharmacokinetic study (n=28) investigated the effects of oral LSD doses of 85 and 170 μg on healthy participants over 24 hours. The results showed mean maximal LSD concentrations of 1.8 ng/ml and 3.4 ng/ml for the respective doses, reaching peak concentrations after approximately 1.7 hours. Elimination half-lives were between 3.7 and 4.0 hours. Only 1% of LSD was found unchanged in urine within 24 hours, while 16% was eliminated as 2-oxo-3-hydroxy-LSD. Subjective effects lasted between 9.3 and 11 hours, with intensity peaking at 77% and 87% for the two doses.

Abstract of Pharmacokinetics, pharmacodynamics & urinary recovery of oral LSD

Aim Lysergic acid diethylamide (LSD) is currently investigated for several neurological and psychiatric illnesses. Various studies have investigated the pharmacokinetics and the pharmacokinetic-pharmacodynamic relationship of LSD in healthy participants, but data on urinary recovery and confirmatory studies are missing.

Method The present study characterized the pharmacokinetics, pharmacokinetic-pharmacodynamic relationship, and urinary recovery of LSD at doses of 85 and 170 μg administered orally in 28 healthy participants. The plasma concentrations and subjective effects of LSD were continuously evaluated over a period of 24 hours. Urine was collected during three time-intervals (0-8, 8-16, and 16-24h after LSD administration). Pharmacokinetic parameters were determined using compartmental modeling. Concentration-subjective effect relationships were described using pharmacokinetic-pharmacodynamic modeling.

Results Mean (95% confidence interval) maximal LSD concentrations were 1.8 ng/ml (1.6-2.0) and 3.4 ng/ml (3.0-3.8) after the administration of 85 and 170 μg LSD, respectively. Maximal concentrations were achieved on average after 1.7 h. Elimination half-lives were 3.7h (3.4-4.1) and 4.0h (3.6-4.4), for 85 and 170 μg LSD, respectively. Only 1% of the administered dose was recovered from urine unchanged within the first 24 hours, 16% was eliminated as 2-oxo-3-hydroxy-LSD (O-H-LSD). Urinary recovery was dose-proportional. Mean (±SD) durations of subjective effects were 9.3±3.2 h and 11±3.7 h, and maximal effects (“any drug” effects) were 77%±18% and 87%±13% after 85 and 170 μg of LSD, respectively.

Conclusion The present novel study validates previous findings. LSD exhibited dose-proportional pharmacokinetics and first-order elimination kinetics and dose-dependent duration and intensity of subjective effects. LSD is extensively metabolized and shows dose-proportional urinary recovery.

Authors: Friederike Holze, Livio Erne, Urs Duthaler & Matthias E. Liechti

Find this paper

Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide (LSD) administration in healthy participants

https://doi.org/10.1111/bcp.15887

Open Access | Google Scholar | Backup | 🕊

Cite this paper (APA)

Holze, F., Erne, L., Duthaler, U., & Liechti, M. E. (2023). Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide (LSD) administration in healthy participants. British Journal of Clinical Pharmacology.

Study details

Compounds studied
LSD

Topics studied
Healthy Subjects

Study characteristics
Original Placebo-Controlled Double-Blind Within-Subject Randomized

Participants
28 Humans

Authors

Authors associated with this publication with profiles on Blossom

Matthias Liechti
Matthias Emanuel Liechti is the research group leader at the Liechti Lab at the University of Basel.

Institutes

Institutes associated with this publication

University of Basel
The University of Basel Department of Biomedicine hosts the Liechti Lab research group, headed by Matthias Liechti.

Compound Details

The psychedelics given at which dose and how many times

LSD 85 - 170
μg | 2x

Linked Research Papers

Notable research papers that build on or are influenced by this paper

Pharmacokinetics and concentration-effect relationship of oral LSD in humans
This double-blind, placebo-controlled, within-subjects study (n=16) evaluated the pharmacokinetic profile of oral LSD (200 μg) in humans. The analysis found that the acute subjective and sympathomimetic effects of LSD lasted for up to 12 hours and were closely linked to the plasma concentrations over time and showed no acute tolerance. This is the first such study and can act as a potential reference for the assessment of intoxication with LSD.

Linked Clinical Trial

Direct Comparison of Altered States of Consciousness Induced by LSD and Psilocybin
The investigators will compare the acute effects of LSD, psilocybin and placebo.

PDF of Pharmacokinetics, pharmacodynamics and urinary recovery of oral lysergic acid diethylamide (LSD) administration in healthy participants